Hypertension Trial, Recruiting NCT07517302 Sponsor: Peking University People's Hospital Condition: Hypertension
Back to Hypertension

Hypertension Trial, Recruiting

NCT07517302
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who are 40 years of age or older
  • People who have been diagnosed with a specific type of glaucoma called chronic primary angle-closure glaucoma (CPACG), confirmed by eye examination showing a certain pattern of eye changes alongside damage to the optic nerve and vision loss in specific areas
  • People who have a cataract significant enough to affect everyday activities and for whom cataract removal surgery has been determined to be necessary
  • People whose eye pressure is not well controlled — either remaining too high (above 21 mmHg) despite taking the maximum tolerated glaucoma medications, or staying at an acceptable level only because of ongoing use of two or more eye drop medications

Who may not be able to join:

  • People whose angle-closure glaucoma is caused by another underlying condition, such as abnormal blood vessel growth, eye inflammation, or lens-related problems
  • People who have previously had surgery inside the eye or a surgical procedure specifically to treat glaucoma (note: a prior laser procedure called laser peripheral iridotomy, if uncomplicated, does not appear to disqualify someone — confirm with trial site)
  • People who have serious eye conditions beyond glaucoma that could significantly affect vision or make it difficult to measure the effect of the trial, such as advanced diabetic eye disease, advanced macular degeneration, or optic nerve damage from a cause other than glaucoma
  • People whose cornea (the clear front surface of the eye) has a low cell count, specifically fewer than 1,500 cells per square millimetre, which may raise safety concerns for the planned procedure
  • People with serious health conditions that would make surgery unsafe or make it difficult to attend follow-up appointments over the 12-month study period

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: 8613621338839

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Peking University People's Hospital
Registry
ClinicalTrials.gov
Start date
1 March 2025
Est. completion
1 September 2025

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Intraocular pressure

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov